Abstract
Chemotherapy-related cardiac dysfunction (CRCD) has challenged clinicians to hesitate in using cardiotoxic agents such as anthracycline and several protein kinase inhibitors. As early detection of CRCD and timely cessation of cardiotoxic agents became a strategy to avoid CRCD, cardiac troponin and natriuretic peptide are measured to monitor cardiotoxicity; however, there are inconsistencies in their predictability of CRCD. Alternative biomarkers have been researched extensively for potential use as more sensitive and accurate biomarkers. The mechanisms of CRCD and previous studies on traditional and novel biomarkers for CRCD are examined to enlighten future direction of investigation in this combined biology.
Original language | English |
---|---|
Pages (from-to) | 381-401 |
Number of pages | 21 |
Journal | Heart Failure Clinics |
Volume | 13 |
Issue number | 2 |
DOIs | |
Publication status | Published - 2017 Apr 1 |
Keywords
- Biomarkers
- Chemotherapy-related cardiac dysfunction
- Heart failure
- Malignancy
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine